Analysts Expect Acorda Therapeutics Inc (ACOR) Will Announce Earnings of -$0.97 Per Share

Wall Street analysts predict that Acorda Therapeutics Inc (NASDAQ:ACOR) will report ($0.97) earnings per share for the current quarter, Zacks reports. Four analysts have provided estimates for Acorda Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.85) and the lowest estimate coming in at ($1.04). Acorda Therapeutics reported earnings per share of $0.14 in the same quarter last year, which would suggest a negative year over year growth rate of 792.9%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, May 1st.

On average, analysts expect that Acorda Therapeutics will report full year earnings of ($3.84) per share for the current year, with EPS estimates ranging from ($4.20) to ($3.30). For the next financial year, analysts forecast that the business will report earnings of ($3.32) per share, with EPS estimates ranging from ($4.31) to ($2.70). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Thursday, February 14th. The biopharmaceutical company reported $0.45 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.19) by $1.64. Acorda Therapeutics had a return on equity of 12.98% and a net margin of 7.14%. The company had revenue of $69.20 million during the quarter, compared to analysts’ expectations of $48.12 million. During the same quarter in the previous year, the business earned $0.61 earnings per share. The firm’s revenue for the quarter was down 63.3% on a year-over-year basis.

A number of brokerages have weighed in on ACOR. Cowen reiterated a “buy” rating and issued a $30.00 price objective on shares of Acorda Therapeutics in a research note on Monday, January 7th. HC Wainwright set a $33.00 target price on Acorda Therapeutics and gave the company a “buy” rating in a report on Monday, January 14th. Oppenheimer set a $18.00 target price on Acorda Therapeutics and gave the company a “hold” rating in a report on Wednesday, January 2nd. Cantor Fitzgerald set a $32.00 target price on Acorda Therapeutics and gave the company a “hold” rating in a report on Wednesday, January 2nd. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of Acorda Therapeutics in a report on Wednesday, January 2nd. Four research analysts have rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the stock. Acorda Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $22.56.

In other news, major shareholder Scopia Capital Management Lp sold 100,000 shares of the business’s stock in a transaction that occurred on Thursday, January 17th. The stock was sold at an average price of $16.86, for a total value of $1,686,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 216,605 shares of company stock worth $3,550,802. Corporate insiders own 7.80% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. American Century Companies Inc. grew its holdings in Acorda Therapeutics by 13.9% during the fourth quarter. American Century Companies Inc. now owns 163,432 shares of the biopharmaceutical company’s stock worth $2,546,000 after acquiring an additional 19,909 shares during the period. Norges Bank acquired a new position in Acorda Therapeutics during the fourth quarter worth $14,675,000. Public Employees Retirement System of Ohio grew its holdings in Acorda Therapeutics by 139.5% during the fourth quarter. Public Employees Retirement System of Ohio now owns 21,915 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 12,764 shares during the period. Municipal Employees Retirement System of Michigan acquired a new position in Acorda Therapeutics during the fourth quarter worth $175,000. Finally, Metropolitan Life Insurance Co. NY grew its holdings in Acorda Therapeutics by 369.0% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 14,539 shares of the biopharmaceutical company’s stock worth $227,000 after acquiring an additional 11,439 shares during the period.

NASDAQ ACOR traded up $0.01 on Thursday, reaching $11.93. The stock had a trading volume of 801,696 shares, compared to its average volume of 867,714. The company has a current ratio of 3.77, a quick ratio of 3.56 and a debt-to-equity ratio of 0.56. Acorda Therapeutics has a 12-month low of $11.81 and a 12-month high of $36.35. The stock has a market cap of $567.75 million, a P/E ratio of 6.55 and a beta of 1.47.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Recommended Story: What is dollar cost averaging (DCA)?

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit